ONCOassist Universal Link Opening ONCOassist app...

🔷 Relacorilant, a selective glucocorticoid receptor antagonist, enhances chemotherapy activity through cortisol pathway modulation, offering a promising new approach for patients with limited therapeutic alternatives.

🔗 Read more: bit.ly/ONCOnews-27M...

#ONCOnews #OncoAlert #OncEd #FDAApproval

Corcept Gains FDA Approval for Cancer Therapy Corcept received FDA approval on Mar 25, 2026; shares rose ~28% intraday and market cap expanded by ~$600m, accelerating commercial and strategic options for the company.

Corcept Gains FDA Approval for Cancer Therapy: Corcept received FDA approval on Mar 25, 2026; shares rose ~28% intraday and market cap expanded by ~$600m, accelerating commercial and strategic options for… 👈 Read full analysis #Corcept #FDAApproval #CancerTherapy #PharmaNews #HealthcareInnovation

ONCOassist Universal Link Opening ONCOassist app...

🔗 Read more: bit.ly/ONCOnews-19M...

#ONCOnews #OncoAlert #OncEd #OvarianCancer #CancerResearch #Oncology #PrecisionMedicine #PersonalizedMedicine #CompanionDiagnostics #Biomarkers #TargetedTherapy #CancerCare #OncologyNews #ClinicalTrials #DrugDevelopment #FDAApproval #PharmaNews #MedTech

J&J gets FDA okay for psoriasis drug icotrokinra Johnson & Johnson's much-anticipated oral IL-23 drug, icotrokinra, has claimed FDA approval as Icotyde for first-line treatment of plaque psoriasis.

#JohnsonandJohnson's much-anticipated oral IL-23 inhibitor, #icotrokinra, has claimed #FDAapproval as a first-line treatment for #plaquepsoriasis.

GSK's RSV shot cleared in US for all adults GSK is back on level pegging with its rivals in the RSV vaccine category in the US, after getting FDA approval for Arexvy in the 18 to 49 age bracket.

#GSK is back on level pegging with its rivals in the #respiratorysyncytialvirus (RSV) vaccine category in the #US, after getting #FDAapproval for the 18 to 49 age bracket.

pharmaphorum.com/news/gsks-rs...

🚨 Latest #FDAApproval Update!

🔷 The FDA has approved teclistamab in combination with daratumumab hyaluronidase-fihj for patients with relapsed or refractory multiple myeloma, expanding treatment options in the later-line setting.

Ascendis scores FDA approval for weekly dwarfism drug Children with achondroplasia will soon have the option of a once-weekly - rather than daily - injection, courtesy of Ascendis' newly approved Yuviwel.

Denmark's #AscendisPharma is planning to #launch its once-weekly therapy for a form of #dwarfism in the #US in the second quarter, after securing #FDAapproval for the drug.

Zongertinib Approved by FDA for HER2+ NSCLC Zongertinib receives FDA accelerated approval for advanced HER2-mutant NSCLC, expanding targeted treatment options.

Zongertinib Receives FDA Accelerated Approval in HER2-Mutant NSCLC

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #NSCLC #MedEd #MedOnc #MedNews #LungCancer #HER2 #TargetedTherapy #FDAApproval

🔷 This first all-oral, fixed-duration (14 cycles), chemo-free regimen reduced progression/death risk by 35% vs.chemoimmunotherapy in the AMPLIFY study (HR 0.65; p=0.0038)

🔗 Read more: bit.ly/ONCOnews23Fe...

#ONCOnews #OncoAlert #OncEd #FDAApproval #CLL #Leukemia #Hematology #Oncology #Cancer

🔷 If approved, giredestrant could offer a targeted endocrine therapy option designed to overcome resistance associated with ESR1 mutations in HR-positive disease.

🔗 Read more: bit.ly/ONCOnews23Fe...

#ONCOnews #OncoAlert #OncEd #FDAApproval #BreastCancer #BreastCancerAwareness #Oncology

Cingulate CEO Shane Schaffer talks about the financing environment for small cap life sciences companies & its recent raise. $CING
#PrecisionTimedRelease #PTR #NASDAQ #Biotech #BioPharma #FDA #FDAApproval #PDUFA #NDA #DrugDelivery #ExtendedRelease #ControlledRelease
youtube.com/shorts/CZ-Cn...

ONCOassist Universal Link Opening ONCOassist app...

🔷 If approved, iberdomide could offer a novel treatment option for heavily pretreated patients with limited therapeutic choices.

🔗 Read more: bit.ly/ONCOnews18Fe...

#ONCOnews #OncoAlert #OncEd #MultipleMyeloma #Hematology #Oncology #CancerResearch #CancerTreatment #FDA #FDAApproval

EVP and Chief Commercial Officer Bryan Downey describes Cingulate’s sales and marketing strategy for CTx-1301. $CING #CTx-1301 #ADHD #PrecisionTimedRelease #PTR #NASDAQ #Biotech #BioPharma #FDA #FDAApproval #PDUFA #NDA #DrugDelivery #ExtendedRelease #ControlledRelease
youtube.com/shorts/sVbvZ...

Cingulate’s SVP of Market Access Rick Arce makes the case for CTx-1301 to payors we move towards the May 31 2026 target action date.
$CING
#PrecisionTimedRelease #PTR #NASDAQ #Biotech #BioPharma #FDA #FDAApproval #PDUFA #NDA #DrugDelivery
youtube.com/shorts/aKWRi...

ONCOassist Universal Link Opening ONCOassist app...

🔷 Introduces Tumor Treating Fields (TTFields) therapy, a novel, noninvasive, biophysical treatment modality.

🔗 Read more: bit.ly/ONCOnews12Fe...

#ONCOnews #OncoAlert #OncEd #FDAApproval #PancreaticCancer #TumorTreatingFields #Oncology #CancerInnovation #LocallyAdvanced #MedTech #CancerCare

This approval supports biomarker-driven treatment selection and expands access to precision immunotherapy in advanced gynecologic cancers.

🔗 Read more: bit.ly/ONCOnews12Fe...

#ONCOnews #OncoAlert #OncEd #FDAApproval #CompanionDiagnostics #PrecisionOncology #OvarianCancer #GynecologicOncology

age1 leads Series C as Loyal advances LOY-002 toward FDA approval, completing key requirements for conditional approval.

vist.ly/4r96v

#longevity #CanineHealth #VeterinaryMedicine #BiotechFunding #HealthyAging #FDAApproval #PetLongevity #DrugDevelopment

EVP and Chief Commercial Officer Bryan Downey explains Indegene’s role in Cingulate’s commercialization efforts for CTx-1301 in ADHD. $CING
#PrecisionTimedRelease #PTR #NASDAQ #Biotech #BioPharma #FDA #FDAApproval #PDUFA #NDA #ControlledRelease #Dexmethylphenidate
youtube.com/shorts/UnnYM...

🔷 This update reflects growing evidence supporting CAR T-cell therapy in a high-risk population with limited treatment options, marking a meaningful step forward in CNS lymphoma care.

🔗 Read more: bit.ly/ONCOnews09Fe...

#ONCOnews #OncoAlert #OncEd #FDAApproval #CNSLymphoma #Oncology #Hematology

As we advance to CTx-1301’s 31May26 target action date, Cingulate SVP of Market Access Rick Arce explains the process of getting payors on board. $CING
#PrecisionTimedRelease #PTR #NASDAQ #Biotech #BioPharma #FDA #FDAApproval #PDUFA #NDA #DrugDelivery #Dexmethylphenidate
youtube.com/shorts/T-fYV...

Cube Click Secures FDA Approval for SMILE Dx - Dentistry Today Cube Click, Inc. is excited to announce that its flagship medical device, SMILE Dx, has received official approval from the U.S. Food and Drug Administration (FDA). SMILE Dx is a next-generation, AI-p...

"Cube Click, Inc. is excited to announce that its flagship medical device, SMILE Dx, has received official approval from the U.S. Food and Drug Administration (FDA)." www.dentistrytoday.com/cube-click-s... #fda #FDAApproval #DentalCare #Dentistry #Dentists #OralHealth #DentalAI #Diagnostics

FDA prior notices shouldn't take hours....automate them with PriorNotify!

Learn more at PriorNotify.com

#FDA
#FDAapproval
#priornotice
#PNSI

🚨 Latest #FDAApproval Update!

🔷 FDA grants Fast Track designation to QTX-2101, an investigational oral arsenic trioxide capsule targeting acute promyelocytic leukemia (APL), a rare, rapidly progressive acute myeloid leukemia (AML) subtype with high bleeding risk.

GRAIL's Submission to FDA Marks a Step Forward for Multi-Cancer Detection with Galleri Test GRAIL, Inc. has taken a monumental step by submitting its Galleri multi-cancer early detection test for FDA approval, aiming for early cancer diagnosis.

GRAIL's Submission to FDA Marks a Step Forward for Multi-Cancer Detection with Galleri Test #USA #Menlo_Park #FDAApproval #GRAIL #Galleri

👁‍🗨Just in! The FDA has approved Yuvezzi, the first dual-agent eye drop for presbyopia.

The carbachol and brimonidine combo showed significant near vision improvement with favorable tolerability in phase 3 trials.

Read more: https://ow.ly/45N150Y5qJW
#Presbyopia #Ophthalmology #FDAApproval

🚨 The New #FDAApproval Alert!

🔹 Shorla Oncology® receives U.S. FDA approval for a larger vial size of nelarabine for IV treatment of T-cell Acute Lymphoblastic Leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL).

🚨 The latest #FDAApproval Alert!

🔹 FDA approved daratumumab and hyaluronidase-fihj in combination with bortezomib, lenalidomide, and dexamethasone (DARZALEX FASPRO-VRd) for patients with newly diagnosed multiple myeloma.

🚨 The latest #FDAApproval Alert!

🔹 Guardant Health’s Guardant360® CDx is now FDA-approved as a companion diagnostic for BRAFTOVI® (encorafenib)–based therapy in patients with BRAF V600E-mutant metastatic colorectal cancer.

BioticsAI's AI-driven fetal ultrasound software secures FDA approval, marking a significant leap in prenatal diagnostics. #BioticsAI #FDAApproval #PrenatalCare #AIinHealthcare Link: thedailytechfeed.com/bioticsai-se...

Stereotaxis MAGiC catheter cleared by FDA for robotic heart ablation The US FDA approves Stereotaxis' robotic magnetic navigation catheter for complex cardiac arrhythmia procedures.

FDA approves Stereotaxis MAGiC robotic ablation catheter. A breakthrough for treating complex heart arrhythmias with precise magnetic navigation.
#News #Stereotaxis #FDAapproval #cardiology #robotics #arrhythmia #healthtech